Role of Glutathione in the Regulation of Cisplatin Resistance in Cancer Chemotherapy

Overview

Journal Met Based Drugs

Specialty Chemistry

Date 2010 Oct 2

PMID 20885916

Citations 116

Authors

Helen H W Chen

Macus Tien Kuo

Affiliations

Soon will be listed here.

Abstract

Three mechanisms have been proposed for the role of glutathione (GSH) in regulating cisplatin (CDDP) sensitivities that affects its ultimate cell-killing ability: (i) GSH may serve as a cofactor in facilitating multidrug resistance protein 2- (MRP2-) mediated CDDP efflux in mammalian cells, since MRP2-transfected cells were shown to confer CDDP resistance; (ii) GSH may serve as a redox-regulating cytoprotector based on the observations that many CDDP-resistant cells overexpress GSH and γ-glutamylcysteine synthesis (γ-GCS), the rate-limiting enzyme for GSH biosynthesis; (iii) GSH may function as a copper (Cu) chelator. Elevated GSH expression depletes the cellular bioavailable Cu pool, resulting in upregulation of the high-affinity Cu transporter (hCtr1) which is also a CDDP transporter. This has been demonstrated that overexpression of GSH by transfection with γ-GCS conferred sensitization to CDDP toxicity. This review describes how these three models were developed and critically reviews their importance to overall CDDP cytotoxicity in cancer cell treatments.

Citing Articles

A Rare Presentation of Five Primary Cancers in a Patient With Werner Syndrome: A Case Report and Literature Review.

Yadav R, Raman S, Saparov D, Yadav V, Boris A Cureus. 2025; 17(1):e77534.

PMID: 39958080 PMC: 11829512. DOI: 10.7759/cureus.77534.

The prognostic importance of the negative regulators of ferroptosis, GPX4 and HSPB1, in patients with colorectal cancer.

Shimura T, Yin C, Ma R, Zhang A, Nagai Y, Shiratori A Oncol Lett. 2025; 29(3):144.

PMID: 39850719 PMC: 11755263. DOI: 10.3892/ol.2025.14890.

DNA Damage Response Network and Intracellular Redox Status in the Clinical Outcome of Patients with Lung Cancer.

Mavroeidi D, Georganta A, Stefanou D, Papanikolaou C, Syrigos K, Souliotis V Cancers (Basel). 2025; 16(24.

PMID: 39766117 PMC: 11726754. DOI: 10.3390/cancers16244218.

Regulation of volume-regulated anion channels alters sensitivity to platinum chemotherapy.

Feldman L, Mohapatra S, Jones R, Scholtes M, Tilton C, Orman M Sci Adv. 2024; 10(50):eadr9364.

PMID: 39671496 PMC: 11641020. DOI: 10.1126/sciadv.adr9364.

Recent development of nanotechnology-based approaches for gynecologic cancer therapy.

Gedda G, Park Y, Pang M Obstet Gynecol Sci. 2024; 68(1):18-29.

PMID: 39591955 PMC: 11788694. DOI: 10.5468/ogs.24180.

References

Tatebe S, Savaraj N, Ishikawa T, Kuo M . Differential sensitivities of the MRP gene family and gamma-glutamylcysteine synthetase to prooxidants in human colorectal carcinoma cell lines with different p53 status. Biochem Pharmacol. 2001; 61(5):555-63. DOI: 10.1016/s0006-2952(00)00592-x. View

Berners-Price S, Kuchel P . Reaction of cis- and trans-[PtCl2(NH3)2] with reduced glutathione inside human red blood cells, studied by 1H and 15N-[1H] DEPT NMR. J Inorg Biochem. 1990; 38(4):327-45. DOI: 10.1016/0162-0134(90)80006-j. View

Yao K, Godwin A, Johnson S, Ozols R, ODwyer P, Hamilton T . Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines. Cancer Res. 1995; 55(19):4367-74. View

Hassett R, Dix D, Eide D, Kosman D . The Fe(II) permease Fet4p functions as a low affinity copper transporter and supports normal copper trafficking in Saccharomyces cerevisiae. Biochem J. 2000; 351 Pt 2:477-84. PMC: 1221384. View

Sasada T, Nakamura H, Ueda S, Iwata S, Ueno M, Takabayashi A . Secretion of thioredoxin enhances cellular resistance to cis-diamminedichloroplatinum (II). Antioxid Redox Signal. 2001; 2(4):695-705. DOI: 10.1089/ars.2000.2.4-695. View

Wang D, Lippard S . Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005; 4(4):307-20. DOI: 10.1038/nrd1691. View

Tatebe S, Unate H, Sinicrope F, Sakatani T, Sugamura K, Makino M . Expression of heavy subunit of gamma-glutamylcysteine synthetase (gamma-GCSh) in human colorectal carcinoma. Int J Cancer. 2002; 97(1):21-7. DOI: 10.1002/ijc.1574. View

Ooi C, Rabinovich E, Dancis A, Bonifacino J, Klausner R . Copper-dependent degradation of the Saccharomyces cerevisiae plasma membrane copper transporter Ctr1p in the apparent absence of endocytosis. EMBO J. 1996; 15(14):3515-23. PMC: 451948. View

Zhang D, Hannink M . Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol Cell Biol. 2003; 23(22):8137-51. PMC: 262403. DOI: 10.1128/MCB.23.22.8137-8151.2003. View

10.

Ishida S, Lee J, Thiele D, Herskowitz I . Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A. 2002; 99(22):14298-302. PMC: 137878. DOI: 10.1073/pnas.162491399. View

11.

Hussain S, Ma Y, Cullen M . Management of metastatic germ cell tumors. Expert Rev Anticancer Ther. 2008; 8(5):771-84. DOI: 10.1586/14737140.8.5.771. View

12.

Garrick M, Dolan K, Horbinski C, Ghio A, Higgins D, Porubcin M . DMT1: a mammalian transporter for multiple metals. Biometals. 2003; 16(1):41-54. DOI: 10.1023/a:1020702213099. View

13.

Siddik Z . Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003; 22(47):7265-79. DOI: 10.1038/sj.onc.1206933. View

14.

Demeule M, Brossard M, Beliveau R . Cisplatin induces renal expression of P-glycoprotein and canalicular multispecific organic anion transporter. Am J Physiol. 1999; 277(6):F832-40. DOI: 10.1152/ajprenal.1999.277.6.F832. View

15.

Kuo M . Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal. 2008; 11(1):99-133. PMC: 2577715. DOI: 10.1089/ars.2008.2095. View

16.

Ikegami Y, Tatebe S, Xie Q, Ishikawa T, Kuo M . Induction of MRP1 and gamma-glutamylcysteine synthetase gene expression by interleukin 1beta is mediated by nitric oxide-related signalings in human colorectal cancer cells. J Cell Physiol. 2000; 185(2):293-301. DOI: 10.1002/1097-4652(200011)185:2<293::AID-JCP14>3.0.CO;2-C. View

17.

Moore D, Tian C, Monk B, Long H, Omura G, Bloss J . Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2009; 116(1):44-9. PMC: 4470610. DOI: 10.1016/j.ygyno.2009.09.006. View

18.

Kauffmann H, Keppler D, Kartenbeck J, Schrenk D . Induction of cMrp/cMoat gene expression by cisplatin, 2-acetylaminofluorene, or cycloheximide in rat hepatocytes. Hepatology. 1997; 26(4):980-5. DOI: 10.1002/hep.510260427. View

19.

Ikeda K, Miura K, Himeno S, Imura N, Naganuma A . Glutathione content is correlated with the sensitivity of lines of PC12 cells to cisplatin without a corresponding change in the accumulation of platinum. Mol Cell Biochem. 2001; 219(1-2):51-6. DOI: 10.1023/a:1011083429704. View

20.

Paulusma C, van Geer M, Evers R, Heijn M, Ottenhoff R, Borst P . Canalicular multispecific organic anion transporter/multidrug resistance protein 2 mediates low-affinity transport of reduced glutathione. Biochem J. 1999; 338 ( Pt 2):393-401. PMC: 1220065. View